Skip to main content
. Author manuscript; available in PMC: 2017 Oct 18.
Published in final edited form as: J Am Stat Assoc. 2016 Oct 18;111(515):921–935. doi: 10.1080/01621459.2015.1086353

Figure 7.

Figure 7

AML-MDS trial data in transition (P, D): Panels (a) and (c) show the posterior estimated survival functions of patient at age 46 and 76 with poor cytogenetic abnormality assigned to salvage treatment HDAC for four induction therapies respectively. Panels (b) and (d) show the posterior estimated survival functions of patient at age 46 and 76 with poor cytogenetic abnormality assigned to salvage treatment non HDAC for four induction therapies respectively. Black, red, green and blue curves represent induction treatments FAI, FAI+ATRA, FAI+GCSF and FAI+ATRA+GCSF, respectively.